The potential for the abuse of drugs such as Ozempic and Wegovy, from the class of GLP-1 medications, has been monitored by Wada since 2024
Combined, GLP1-related projects could contribute around $1B of annual revenue by FY32, helping lift Divis total sales towards roughly $2.7B and restoring EBITDA margins above 40%
Learn it once and you never need to memorize a chart again
As UK researchers move beyond Semaglutide and Tirzepatide, Retatrutide stands apart as the only triple-receptor agonist available from a UK supplier with independently verified certificates of analysis
The real annual cost: Piper vs Gala vs PlexusDx Sticker prices on landing pages are misleading because commitment length, plan tier, and dose-included rules differ across providers
As prescription GLP 1 medications gain attention for their metabolic benefits, patch-based alternatives are increasingly marketed as a convenient solution